NCT03623867View on ClinicalTrials.gov

PsA Secukinumab XCT Structural Progression Study

PHASE4CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

May 18, 2020

Primary Completion Date

September 30, 2022

Study Completion Date

September 30, 2022

Conditions
Psoriatic Arthritis
Interventions
DRUG

Secukinumab

Subject will take secukinumab once weekly in week 0-4, and once monthly till week 48

DRUG

Placebo

Subject will take placebo once weekly in week 0-4, and once monthly till week 48

Trial Locations (1)

Unknown

Department of Medicine and Therapeutics, Hong Kong

All Listed Sponsors
lead

Chinese University of Hong Kong

OTHER

NCT03623867 - PsA Secukinumab XCT Structural Progression Study | Biotech Hunter | Biotech Hunter